Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.03 -0.50%

-$0.14 today

Market cap
$465.03M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 8.33M

Average 1.08M

CAPR Account Payables

Amounts the company owes suppliers for goods and services received.

Capricor Therapeutics, Inc.NASDAQ: CAPR

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 25.2% from a year ago

Account payables stood at $3.93M at the end of Q1 FY2026, down 25.2% from a year earlier and up 137.4% from the prior quarter. Over 3 fiscal years it compounded at -30.0% a year.

Context

  • Account payables amounted to 1.2% of total assets at the end of Q1 FY2026, down 2.2 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -25.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.93M+137.4% QoQ
Last fiscal yearDec 2025
$1.65M-49.6% YoY
Year agoMar 2025
$5.25M-25.2% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.2%——
1 year-49.6%——
3-year CAGR-30.0%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
1.65M USD
Year-over-year change
-49.6%
4-year CAGR
-18.3%

Account Payables vs competitors

How CAPR compares with its peers on the latest reported figures

  • CAPR's Mar 2026 account payables of $3.93M is the 8th highest of the 10 companies compared; the peer median is $12.15M.
  • Its year-over-year change of -25.2% is the 8th highest of 10, against a peer median of +32.8%.
  • Account payables amounts to 1.2% of total assets for CAPR, versus a peer median of 1.2%.
CAPR Competitors Peer median
Account Payables for CAPR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SRPTSarepta Therapeutics, Inc.Mar 2026$70.38M -54.9%+43.1%2.2%
PTCTPTC Therapeutics, Inc.Jun 2026$40.45M +52.6%+18.6%1.2%
IONSIonis Pharmaceuticals, Inc.Sep 2026$27.11M +89.3%+16.2%0.9%
WVEWave Life Sciences Ltd.Mar 2026$19.06M +32.8%-2.5%3.3%
DYNDyne Therapeutics, Inc.Jun 2026$12.15M -13.3%+15.4%1.2%
EWTXEdgewise Therapeutics, Inc.Sep 2026$9.64M +56.6%-0.5%0.5%
SLDBSolid Biosciences Inc.Mar 2026$5.56M -13.6%-0.1%1.3%
CAPRCapricor Therapeutics, Inc.Mar 2026$3.93M -25.2%-30.0%1.2%
TRDAEntrada Therapeutics, Inc.Mar 2026$2.93M +33.9%-27.4%0.9%
PEPGPepGen Inc.Mar 2026$622K -77.0%-15.5%0.4%
Peer median (excluding CAPR) $12.15M+32.8%-0.1%1.2%

Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents34.89M9.6M14.69M11.29M287.85M
Short-term Investments031.82M24.79M140.23M30.28M
Net Receivables391.75K547.58K10.37M10.37M59.17K
Inventory00000
Other Current Assets0919.89K000
Total Current Assets36.44M42.89M50.86M163.39M322.94M
Property, Plant & Equipment (Net)4.62M6.94M7.61M6.87M18.31M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets275.72K268.17K268.17K221.7K14.7M
Total Non-current Assets4.89M7.21M7.88M7.1M33.01M
Total Assets41.33M50.09M58.73M170.48M355.95M
Account Payables3.72M4.83M6.24M3.28M1.65M
Short-term Debt417.63K682.04K749.11K834.8K3.62M
Tax Payables00000
Deferred Revenue017.98M24.27M12M12M
Other Current Liabilities0002.36M11.85M
Total Current Liabilities4.13M23.59M31.27M21.03M35.84M
Long-term Debt3.38M3.38M3.38M3.38M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)09.47M000
Other Non-current Liabilities00000
Total Non-current Liabilities5.83M14.72M4.86M3.99M14.32M
Total Liabilities9.96M38.31M36.13M25.02M50.16M
Common Stock24.19K25.24K31.15K45.58K57.37K
Retained Earnings(108.06M)(137.08M)(159.37M)(199.83M)(304.88M)
Accumulated OCI0105.24K235.81K1.03M283.15K
Other Stockholders Equity(0)0100
Minority Interest00000
Total Equity31.37M11.79M22.6M145.46M305.79M
Total Debt6.25M5.94M5.61M4.83M17.94M
Net Debt(28.64M)(3.67M)(9.08M)(6.46M)(269.9M)

Capricor Therapeutics, Inc.

NASDAQ:CAPR

Intrinsic Alpha fair value

Locked

Current Price

$8.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.